Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 25,190 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PRE Clear all

Conditions: Freezing of Gait Symptoms in Parkinson Disease
Interventions: Active Stimulation, Sham (No Treatment); Device
Lead sponsor: Iahn Cajigas; Other
Eligibility: 35 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: San Francisco, California • Miami, Florida • Philadelphia, Pennsylvania

Conditions: Coronary Arterial Disease (CAD)
Interventions: Cangrelor; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Malocclusion
Interventions: Micro-osteoperforation, Anesthestic, Chlorhexidine; Device · Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
Interventions: Oral repotrectinib (TPX-0005); Drug
Lead sponsor: Turning Point Therapeutics, Inc.; Industry
Eligibility: Up to 25 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 20
States / cities: Los Angeles, California • Aurora, Colorado • Orlando, Florida + 14 more

Conditions: Colorectal Cancer, Colorectal Adenocarcinoma
Interventions: Temsirolimus, Cetuximab; Drug
Lead sponsor: Jeffrey W. Clark, MD; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Thrombocythemia, Essential, Primary Myelofibrosis
Interventions: Bomedemstat; Drug
Lead sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Miami, Florida • Ann Arbor, Michigan • Cleveland, Ohio + 2 more

Conditions: Cerebral Aneurysm
Interventions: Microsurgical clipping, Endovascular treatment, Sirolimus; Procedure · Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Obesity
Interventions: Nasal Placebo, Placebo Capsule, PYY3-36, Sibutramine; Drug
Lead sponsor: Nastech Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 29
States / cities: Peoria, Arizona • Phoenix, Arizona • Anaheim, California + 25 more

Conditions: Autism Spectrum Disorder
Interventions: Intervention Coaching Group; Behavioral
Lead sponsor: Health Resources and Services Administration (HRSA); Federal
Eligibility: Not listed
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Davis, California • Rochester, New York • Philadelphia, Pennsylvania

Conditions: Coagulation Disorder
Interventions: International Normal Ratio (INR); Diagnostic Test
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Soft Tissue Sarcoma
Interventions: Hypofractionated Radiation Therapy; Radiation
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Decisional Conflict
Interventions: Pelvic organ prolapse decision aid; Other
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Solid Tumors
Interventions: Idasanutlin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 9
States / cities: Aurora, Colorado • New Haven, Connecticut • St Louis, Missouri + 5 more

Conditions: Glioblastoma
Interventions: Temozolomide, Neratinib, QBS10072S, Abemaciclib, CC-115; Drug
Lead sponsor: David Reardon, MD; Other
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 12
States / cities: Birmingham, Alabama • Boston, Massachusetts • Rochester, Minnesota + 7 more

Conditions: Locally Advanced Cancer, Metastatic Cancer, HER2, HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, HER 2 Low-expressing Breast Cancer
Interventions: [68Ga]Ga-ABY-025; Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Breast Cancer
Interventions: cisplatin, etoposide, ifosfamide, Mesna; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Not listed
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Type I Diabetes
Interventions: NNC0361-0041, Placebo; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 16
States / cities: Orange, California • San Francisco, California • Stanford, California + 13 more

Conditions: Transfemoral Amputation
Interventions: Northwestern University Flexible Subischial Suction Socket (NU-FlexSIS); Device
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Houston, Texas • Seattle, Washington

Conditions: Cataracts
Interventions: Xibrom, and Optive, Xibrom and Pred Forte; Drug
Lead sponsor: Bp Consulting, Inc; Network
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Tarpon Springs, Florida

Conditions: Elective Abdominal Surgery
Interventions: Remote Patient Monitoring; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 75 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Multiple Sclerosis
Interventions: Cetirizine, Diphenhydramine; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Lymphedema
Interventions: 23-32 mmHg compression sleeve with gauntlet; Device
Lead sponsor: ImpediMed Limited; Industry
Eligibility: 18 Years and older
Enrollment: 1,201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 9
States / cities: Jacksonville, Florida • Kansas City, Kansas • Louisville, Kentucky + 6 more

Conditions: HIV Seropositivity, Bisexuality
Interventions: Tele-B6, Delayed intervention (waitlist control); Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 29 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Multiple Myeloma
Interventions: AMG 224; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 4
States / cities: West Hollywood, California • Boston, Massachusetts • New York, New York + 1 more

Search by objective public record fields.

CnF-DBS for Levodopa-Resistant FOG

The Bridging Antiplatelet Therapy With Cangrelor 2 Study

Alveolar Microperforation for Inflammation-Enhanced Tooth Movement During Orthodontic Treatment

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer

An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)

Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms

A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects

Building Better Bridges Randomized Control Trial

INR Comparison Testing in Cardiac Surgery

Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-wall

Effect of a Decision Aid on Decision Making for the Treatment of Pelvic Organ Prolapse

A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer

A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

Sub-Ischial Socket for Transfemoral Amputation and Lower Mobility

Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care

Remote Monitoring of Surgical Patients Through VALIDIC

Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project

Bioimpedance Spectroscopy Versus Tape Measure in Prevention of Lymphedema (PREVENT)

Telehealth Delivery (Tele-B6)

A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma